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a b s t r a c t
Background: Globally, opioid drug use is an important cause of premature mortality. In many countries,
opioid using populations are ageing. The current study investigates mortality in a large cohort of opioid
users; with a focus on testing whether excess mortality changes with age.
Methods: 198,247 opioid users in England were identiﬁed from drug treatment and criminal justice
sources (April, 2005 to March, 2009) and linked to mortality records. Mortality rates and standardised
mortality ratios (SMRs) were calculated by age-group and gender.
Results: There were 3974 deaths from all causes (SMR 5.7, 95% Conﬁdence Interval: 5.5 to 5.9).
Drug-related poisonings (1715) accounted for 43% of deaths. Relative to gender-and-age-appropriate
expectation, mortality was elevated for a range of major causes including: infectious, respiratory, circu-
latory, liver disease, suicide, and homicide. Drug-related poisoning mortality risk continued to increase
beyond 45 years and there were age-related increases in SMRs for speciﬁc causes of death (infectious,
cancer, liver cirrhosis, and homicide). A gender by age-group interaction revealed that whilst men have a
greater drug-related poisoning mortality risk than women at younger ages, the difference narrows with
increasing age.
Conclusion: Opioid users’ excess mortality persists into old age and for some causes is exacerbated. This
study highlights the importance of managing the complex health needs of older opioid users.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/3.0/).
1. Introduction
Illicit drug use, especially opioid addiction, is an acknowledged
public health problem in most developed countries and a grow-
ing problem worldwide (Degenhardt and Hall, 2012; Degenhardt
et al., 2004; Lim et al., 2013). Deaths due to illicit drug use are an
important, increasing (Murray et al., 2013), and preventable cause
of premature mortality (Bargagli et al., 2006). Recent global esti-
mates suggest that the years of life lost due to illicit drugs are
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greater than for alcohol, because the former tend to occur at an ear-
lier age (Degenhardt and Hall, 2012). In England andWales, deaths
directly attributed to illicit drug use (i.e., drug related poisonings)
account for 12% of all fatalities between 16 and 40 years of age
(Ofﬁce for National Statistics Statistical Bulletin, 2013). The risk of a
drug related poisoning is higher formales, drug injectors and those
with concurrent depressant use (Davoli et al., 2007; Degenhardt
et al., 2011; Merrall et al., 2012). A substantial, international body
of evidence demonstrates excess mortality risk for many causes of
death including: suicide; homicide; infectious disease; and liver-
related disease (Bird, 2010; Crump et al., 2013; Degenhardt et al.,
2014; Ghodse et al., 1998; Merrall et al., 2012).
Statistically powerful studies are required to ascertain which
speciﬁc causes of death are elevated and to identify the key
behavioural and demographic risk factors. Large scale, preferably
national, record linkage studies can address the problem of statis-
tical power, but often exclude non-treatment-seeking individuals.
A recent overview by Degenhardt et al. (2011) identiﬁed the
http://dx.doi.org/10.1016/j.drugalcdep.2014.09.782
0376-8716/© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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exclusion of non-treatment-seeking users and the paucity of
national studies as important limitations of the current literature,
that constrain the capacity to generalise ﬁndings to the wider
population of opioid users.
The ageing population of opioid users is an emerging issue for
treatment services in many developed countries (Gossop, 2008;
Gfroerer et al., 2003). Whilst some studies describe poor health
among older opioid users (Hser et al., 2004; Rosen et al., 2008), few
have investigated mortality according to age-group (Degenhardt
et al., 2011). Degenhardt et al. (2014) recently reported changes in
the distribution of causes of death with age among 43,789 treated
opioid users observed over a 20 year period. They highlight that
disease, such as cancer or liver disease, accounts for an increasing
proportionofdeathswith increasingage, as seen in thegeneralpop-
ulation, but do not provide a measure of how opioid users’ excess
mortality changes with age (i.e., by reference to what would be
expected in the general population).
The study reported here uses data for a large, national opioid
user cohort that includes both treatment and non-treatment seek-
ing individuals. In this studyweaim to: (i) describe excessmortality
due to all-causes and drug-related poisonings; (ii) identify speciﬁc
causes of death which are elevated; (iii) assess whether cause-
speciﬁcmortality risk compared to the general population persists,
decreases or increases with age; (iv) assess whether the difference
in drug related poisoning mortality risk between male and female
opioid users persists with age.
The cohort was drawn from the Drug Data Warehouse (Millar
et al., 2012), an anonymous, case-linked collection of secondary
datasets about substance (drug use and/or alcohol misuse) users in
England and Wales. The Drug Data Warehouse includes data from:
drug treatment services; prison and probation services; criminal
justice referral; anddrug testing on arrest schemes. Internationally,
this is the largest opioid user cohort (n=198,247) forwhommortal-
ity by speciﬁc cause has been reported. The inclusion of treatment
and non-treatment-seeking individuals in a national cohort is both
necessary and novel. This, combinedwith a focus on age effects and
the necessary statistical power to investigate these, addresses key
limitations identiﬁed (Degenhardt et al., 2011) in the literature to
date.
2. Methods
2.1. Population, cohort, and data linkage
Datawere extracted from theDrugDataWarehouse for a cohort
of opioid users, aged 18 to 64 years, actively using or being treated
for opioid use, in England over the period 1st April 2005 to 31st
March 2009. Deaths occurring in the cohort were established by
case linkage to national mortality records.
Table 1 shows case deﬁnitions for cohort inclusion from each
data source. All data sources provided details of age group and
gender.
Record linkage between criminal justice and treatment data
sources used an identiﬁer based on initials, date of birth, and
gender. Additional data available from criminal justice sources pro-
vided evidence of duplicated identiﬁers for 23% of cases (n=58,547
of 256,794); conservatively, all records for these were excluded
from the current analysis. Case-linkage to mortality records used
the additional criterion of region of residence, to increase accuracy.
Linkedmortality records (n=478)were removedwhere evidenceof
new treatment or criminal justice activity, after the apparent date
of death, indicated an erroneous match.
Data were rendered anonymous to the research team, via
irreversible encryption of identifying information, prior to their
release by source organisations.
2.2. Mortality records
The Ofﬁce for National Statistics provided records of deaths
of persons aged 18–64 years occurring during the observation
period 1st April, 2005 to 31st March, 2009 and registered by
30th September, 2011. This allowed for late registration of deaths
referred for investigation by a coroner (Bird, 2013). Underlying
cause was recorded for each death and coded according to the
World Health Organisation’s International Classiﬁcation of Disease
10th revision (ICD-10; WHO, 2011).
2.3. Population data and classiﬁcation of cause of death
Population mortality rates were compiled from mid-year pop-
ulation estimates and published ﬁgures on deaths registered
between 2005 and 2008 for England andWales (Ofﬁce for National
Statistics Statistical Bulletin, 2011) as published data were not
availablebydeath-year for theexact observationperiod. Rateswere
calculated by gender, ﬁve year age-group (15–19, 20–24, 25–29,
30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64), and for under-
lying cause of death.
Drug-related poisoning deaths were deﬁned according to the
Ofﬁce of National Statistics UK harmonised deﬁnition (Ofﬁce for
National Statistics Statistical Bulletin, 2013) which uses the fol-
lowing ICD-10 codes: F11-16, F18-19 (mental and behavioural
disorders due to psychoactive substance use, excluding alcohol and
tobacco); X40-44 (external causes: accidental poisoning by drugs,
medicaments and biological substances); X60-64 (external causes:
intentional self-poisoning drugs, medicaments and biological sub-
stances); X85 (external causes: assault by drugs, medicaments
and biological substances); Y10-14 (external causes: poisoning
by drugs, medicaments and biological substances undetermined
intent).
Table 1
Data sources and selection criteria used to deﬁne the opioid user cohort.
Data source Cohort population Case deﬁnition for opioid use Number of individuals
National drug treatment
monitoring system
Treatment clients receiving community or
residential structured addiction treatment
Reporting opioid use at triage to
treatment
47,707
Drug test on arrest Subjects arrested following a “trigger” offence, or
at police discretion, and then tested for opioids and
cocaine metabolites by saliva sample, in areas
where the drug test on arrest programme operates
Testing positive for opiate use
(indicative of recent use)
54,937
Drug intervention record Persons assessed for referral to structured drug
treatment following identiﬁcation in a criminal
justice setting
Reporting weekly or greater opioid
use at assessment
39,517
Offender assessment system Offenders assessed in prison, or whilst on
probation for needs and risks prior to sentencing,
and at various points throughout their sentence,
including assessment of substance use
Reporting weekly or greater opioid
use at assessment
151,983
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Suicides include deaths of ‘undetermined intent’ (ICD-10: X60-
X84; Y10-Y34). To avoid double counting, drug-related poisoning
mortality was treated as a separate category and were excluded
from reporting of the ICD-10 Chapters ‘external causes’ and ‘mental
and behavioural disorders’.
2.4. Approvals
Use of ofﬁcial mortality records was approved by the Ofﬁce
for National Statistics Microdata Release Panel. Use of data from
the Drug Data Warehouse was authorised by those organisations
providing data. TheNHSCentral Ofﬁce for Research Ethics Commit-
tees and The University of Manchester Research Ethics Committee
advised that further approval was not required for a study of this
type.
2.5. Statistical analysis
Description of measures used: Crude mortality rate (CMR):
Describes the rate of death occurring in the cohort. A CMR of 73 per
10,000 pys translates to 73 deaths occurring among 10,000 peo-
ple over a one-year period or to 73 deaths occurring among 20,000
people over a 6-month period. Standardised Mortality Ratio (SMR):
describes the extent towhichmortality in a cohort differs from that
which would be seen in an ‘average’ population, matched for age
and gender. An SMR of 5.7 means that there were 5.7 times more
deaths occurring in the cohort than would have occurred in a sam-
ple of the general population who had the same distribution of age
and gender.
Crude mortality rates (CMR) per 10,000 person-years (pys)
were calculated for all-cause mortality, and drug-related poison-
ing deaths. An individual’s risk period began at the date of their
earliest observation in the cohort on or after 1st April 2005 and
ceased at the end of data collection (31st March, 2009) or the date
of death, if earlier. Individuals already in treatment on 1st April,
2005 began their time at risk from that date.
Observed deaths (O) were compared to gender and age appro-
priate expected mortality (E) to derive standardised mortality
ratios (SMR=O/E). The expectedmortalitywas calculated bymulti-
plying the (disease speciﬁc) mortality rate observed in the general
population by the person years of follow-up seen in the analysis
cohort, matched by age and gender (indirect method). Conﬁdence
intervals for CMRs and SMRs were calculated using a normal
approximation to the Poisson distribution for the observed number
of deaths. All p values are two sided.
Following strong prior information for drug-related poisonings
(King et al., 2012, 2013), we assessed whether mortality differ-
ences between males and females persist with age by testing for
an interaction between gender and age-group. The interaction was
evaluated by testingwhether the relative risk, comparing the drug-
related poisoning mortality rate between males and females, was
equal across age groups, using a chi-squared test. Evidence for pres-
ence of an interaction was set at p<0.01. As a sensitivity analysis,
we assessed whether evidence for an age and gender interaction
was due to differences in behavioural risk factors by carrying out an
adjusted analysis on the subcohort of treated individuals for whom
we have information available on risk factors (n=151,983). This is
described in the supplementary material1.
Cause-speciﬁc CMRs and SMRs were ﬁrst calculated at the ICD-
10 Chapter level. To retain statistical power the a priori analysis
strategy was to present CMR/SMRs at subsequent ICD-10 lower,
more detailed descriptive levels if (a) the SMR for the higher level
1 Supplementary material can be found by accessing the online version of this
paper at http://dx.doi.org and by entering doi:..
Table 2
Description of opioid user cohort: age, gender, and mortality.
Number of individuals 198,247
Person-years under observation 541,891
Median age at cohort accession date, years [IQR] 32.1 [26.4, 38.7]
Gender (%)
Male 142,608 (72)
Female 55,639 (28)
Age group at cohort entry (%)
18–24 37,172 (19)
25–34 85,725 (43)
35–44 55,005 (28)
45–64 20,345 (10)
All-cause mortality
Number of deaths 3,974
Rate per 10,000 pys [95% CI] 73 [71,76]
Expected deaths 695
SMR [95% CI] 5.7 [5.5, 5.9]
Drug-related poisoning death
Number of deaths 1715
Rate per 10,000 pys [95% CI] 32 [30, 33]
was ≥5; and (b) the expected number of deaths for the lower level
was ≥5. Four additional causes of death were considered at the
lower descriptive level due to their importance in the literature:
suicide, viral hepatitis, liver cancer, and human immunodeﬁciency
virus (HIV) (Darke et al., 2007; Darke and Ross, 2002; Degenhardt
et al., 2011; Merrall et al., 2012).
The relationshipbetweencause-speciﬁcSMRandagewas inves-
tigated, for the entire cohort, using Poisson regression models.
Analyses were undertaken using Stata version 13.
3. Results
3.1. All-cause and drug-related poisoning mortality (Table 2)
The cohort (n=198,247) contributed 541,891 pys of follow up:
the median follow-up time was 3.1 years (Inter Quartile Range
(IQR): 1.7 to 4 years). Themedian age at cohort entrywas 32.1 years
(IQR: 26.4 to 38.7 years), 142,608 (72%) cohortmembersweremale
and 184,256 (93%) were identiﬁed as heroin users (as opposed to
users of other opioids).
Therewere 3974 deaths from all causeswith a CMR of 73 deaths
(95% conﬁdence interval 71 to 76) per 10,000 pys and an SMR of
5.7 (95% CI: 5.5 to 5.9); thus there were more than ﬁve and a half
times the number of deaths than would be expected in the age and
gender appropriate general population.
Drug-related poisonings (CMR 32; 95% CI 30 to 33) were the
most common cause of mortality, accounting for 43% of deaths.
3.2. All-cause and drug-related poisoning mortality by age and
gender (Table 3)
Male all-cause CMR was higher than for females (81 vs. 54,
p<0.001) but males’ SMR was lower (5.5 vs. 6.9, p<0.001), reﬂect-
ing lower female mortality in the general population.
Tables 2–3.
Male drug-related poisoning CMR (35; 95% CI 34 to 37) was
substantially higher than for females (23; 95%CI 21 to 25,p<0.001).
Across gender, drug-related poisoning CMR increasedmarkedly
with age, from 19 (95% CI 16 to 23) at 18–34 years to 45 (95% CI
40 to 50) at 45–64 years (p<0.001) and was higher at 45–64 than
35–44 years (p=0.04).
There was clear evidence to reject the hypothesis that the
male vs. female comparison in drug-related poisoning rate was
equivalent for different age-groups (chi squared (2 dof) = 13.04,
p=0.002). This interaction revealed that males had almost double
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Table 3
All-cause crude mortality rates, standardised mortality ratios and drug-related poisoning mortality rates by age and gender: opioid user cohort of 198,247 individuals and
541,891 person years.
Variable All-cause mortality Drug-related poisoning deaths
Pys,
thousand
Deaths (n) CMR, per 10,000 pys
[95% CI]
Expected
deaths (n)
SMR [95% CI] Deaths (n) CMR, per 10,000 pys
[95% CI]
Gender
Male 383 3,118 81 [79,84] 572 5.5 [5.3, 5.6] 1,353 35 [34,37]
Female 159 856 54 [50,57] 123 6.9 [6.5, 7.4] 375 23 [21,25]
Age-group, time updated
18–24 63 185 30 [26,34] 32 5.7 [5.0, 6.6] 119 19 [16,23]
25–34 236 1,052 45 [42,47] 176 6.0 [5.6, 6.4] 602 26 [24,28]
35–44 175 1,480 84 [80,89] 233 6.3 [6.0, 6.7] 686 39 [36,42]
45–64 68 1,257 184 [174,194] 254 5.0 [4.7, 5.2] 308 45 [40,50]
Age-group males only, time updated
18–34 203 954 47 [44,50] 174 5.5 [5.2, 5.9] 580 29 [26,31]*
35–44 128 1,148 89 [84,95] 192 6.0 [5.7, 6.4] 534 42 [38,45]*
45–64 51 1,016 199 [187,212] 207 4.9 [4.6, 5.2] 239 47 [41,53]*
Age-group females only, time updated
18–34 95 283 30 [27,34] 34 8.3 [7.3, 9.3] 141 15 [13,18]*
35–44 47 332 71 [63,79] 42 7.9 [7.1, 8.8] 152 32 [28,38]*
45–64 17 241 140 [123,158] 47 5.1 [4.5, 5.8] 69 40 [32,51]*
* Males vs. females relative risk at levels of age-group: 18–34: 1.9 (95% CI: 1.6 to 2.3); 35–44: 1.3 (95% CI: 1.1 to 1.5); 45–64: 1.2 (95% CI: 0.9 to 1.5). Test for equality of
relative risks: chi squared (2 dof) = 13.04; p=0.002.
the drug-relating poising CMR compared to females at 18–34 years
(29; 95% CI 26 to 31 vs. 15; 95% CI 13 to 18) but this difference
narrows considerably with age (i.e. at 45–64: 47; 95% CI 41 to 53
vs. 40; 95% CI 32 to 51). This interaction also revealed that there
was a clear difference in drug related poisoning rates at age 35–44
(relative risk males vs. females 1.3, 95% CI 1.1 to 1.5) but this was
less apparent at age 45–64 (relative risk 1.2, 95% CI 0.9 to 1.5).
3.3. Cause-speciﬁc mortality (Table 4a)
CMRs were higher than expected for all ICD-10 classiﬁcations,
except ‘other’ causes. Chapter level SMRs ranged from 1.7 (95% CI
1.3 to 2.3, nervous system diseases) and 1.8 (95% CI 1.6 to 2.0, can-
cers) to 12.6 (95% CI 10.8 to 14.8, infectious/parasitic disease) and
17.2 (95% CI 11.0 to 27.0, skin/subcutaneous tissue disease). The
latter included ﬁve deaths from abscesses and seven from celluli-
tis.
After drug-related poisoning deaths, ‘external causes’ (with
drug-related poisonings excluded) were the most frequent cause
of mortality (21% of all deaths; CMR 8.9; 95% CI 8.1 to 9.7), notably
suicide (drug-related poisonings excluded, 5%) and homicide (2%).
Rates of homicide were 12 times higher (SMR 12.2; 95% CI 9.8 to
15.3) and suicide (where not also classiﬁed as drug-related poison-
ings) three times higher (SMR 2.9; 95% CI 2.5 to 3.4) than expected.
With drug-related poisonings included, the SMR for suicides was
4.3 (95% CI 3.9 to 4.8).
Circulatory and digestive system diseases accounted for similar
proportions of deaths (both 11%) butwithmarkedly different SMRs
(3.1; 95% CI 2.8 to 3.4 vs. 6.4; 95% CI 5.9 to 7.1). Digestive system
mortality was due mainly to diseases of the liver. Respiratory sys-
tem disease was also common, accounting for 7% (CMR 4.8; 95% CI
4.2 to 5.4)with an SMRof 8.9 (95% CI 7.9 to 10.1): half of respiratory
system deaths were due to chronic lower respiratory disease and a
further 39% to inﬂuenza and pneumonia.
Fifteen per cent of the 2259 deaths not categorised as drug-
related poisonings were caused by liver disease (n=345); the
majority alcoholic liver disease (72%) or ﬁbrosis and cirrhosis of
the liver (19%), the latter associated with SMR of 9.6 (95% CI 7.5 to
12.2). Additionally, liver cancer accounted for 38 deaths (SMR 9.2;
95% CI 6.7 to 12.7).
3.4. Cause-speciﬁc mortality by age (Table 4b)
For circulatory, respiratory and digestive system disease, CMRs,
as to be expected, increased sharplywith age. At 35–44 years, CMRs
were highest for circulatory (8.1; 95% CI 6.9 to 9.6) and digestive
system disease (9.3; 95% CI 8.0 to 10.9) but, by 45–64 years, can-
cer (28.0; 95% CI 24.3 to 32.2), circulatory (29.9; 95% CI 26.0 to
34.3) and digestive system (29.3; 95% CI 25.5 to 33.6) deaths dom-
inated, with respiratory deaths close behind (19.2; 95% CI 16.2 to
22.8).
Table 4a.
Table 4b.
The SMR increased markedly with age for infectious/parasitic
disease (5.7; 95% CI 3.8 to 8.6 at 18–34 years to 23.2; 95% CI 18.6 to
28.8 at age 45–64 years, trend p=<0.001), cancers (1.3; 95% CI 0.9
to 1.8 vs. 2.1; 95% CI 1.8 to 2.4, trend p=0.003), and liver ﬁbrosis
and cirrhosis (2.6; 95% CI 0.7 to 10.5 vs. 14.1; 95% CI 10.6 to 18.9,
trend p<0.001), but not for other speciﬁc disease causes.
For homicide, CMR changed little with age but the SMR
increasedmarkedly (p=0.002) from8.8 (95%CI 6.3 to12.2) at 18–34
years to 27 (95% CI 16 to 46) at 45–64 years; thus, older opioid
users were very much more likely to be the victims of homicide
than their counterparts in the general population. Risk of suicide
(drug-related poisoning excluded) was elevated for all age groups,
but SMRs showed no trend with age (p=0.55).
4. Discussion
4.1. Principal ﬁndings
Consistent with previous research, all-cause mortality for
England’s opioid user cohort was highly elevated (SMR 5.7; 95% CI
5.5 to 5.9). Although drug-related poisoning was the predominant
cause, the cohort had elevated risks for all main causes of death.
Our ﬁndings are highly informative for the evidence-base on
age-relatedmortality in active opioid users because 15% of pys, 18%
of drug-related poisoning deaths and 32% of all fatalities occurred
at 45–64 years. Importantly, this study is the ﬁrst to calculate age
trends in excess deaths and we demonstrate that health inequali-
ties persist with increasing age and for some disease causes widen
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Table 4a
Cause-speciﬁc CMRs and SMRs for the opioid user cohort of 198,247 individuals and 541,891 person years.
ICD 10 level Disease description ICD-10 codes* Observed
deaths
CMR, per 10,000
pys [95% CI]
Expected
deaths
SMR [95% CI]
Chapter Infectious/parasitic A00-B99 159 2.9 [2.5, 3.4] 12.6 12.6 [10.8, 14.8]
3 Viral hepatitis B15-B19 82 1.5 [1.2, 1.9] 1.4 57.2 [46.1, 71.1]
3 HIV B20-B24 31 0.6 [0.4, 0.8] 4.4 7.0 [5.0, 10.0]
Chapter Cancers C00-D48 296 5.5 [4.9, 6.1] 166.3 1.8 [1.6, 2.0]
Liver cancer C22 38 0.7 [0.5, 0.9] 4.1 9.2 [6.7, 12.7]
Chapter Endocrine E00-E90 29 0.5 [0.4, 0.8] 12.5 2.3 [1.6, 3.3]
Chapter Mental and behavioural* F00-F99 31 0.6 [0.4, 0.8] 7.2 4.3 [3.0, 6.1]
Chapter Nervous system G00-G99 47 0.9 [0.7, 1.2] 27.4 1.7 [1.3, 2.3]
Chapter Circulatory system I00-I99 418 7.7 [7.0, 8.5] 134.1 3.1 [2.8, 3.4]
Chapter Respiratory system J00-J99 259 4.8 [4.2, 5.4] 29.0 8.9 [7.9, 10.1]
3 Inﬂuenza and pneumonia J09-J18 102 1.9 [1.6, 2.3] 11.6 8.8 [7.2, 10.7]
3 Chronic lower respiratory diseases J40-J47 130 2.4 [2.0, 2.8] 10.4 12.6 [10.6, 14.9]
Chapter Digestive system K00-K93 423 7.8 [7.1, 8.6] 65.7 6.4 [5.9, 7.1]
3 Diseases of liver K70-K77 345 6.4 [5.7, 7.1] 49.5 7.0 [6.3, 7.8]
2 Alcoholic liver disease K70 249 4.6 [4.1, 5.2] 37.1 6.7 [5.9, 7.6]
2 Fibrosis and cirrhosis K74 66 1.2 [1.0, 1.6] 6.9 9.6 [7.5, 12.2]
Chapter Skin and subcutaneous tissue L00-L99 19 0.4 [0.2, 0.5] 1.1 17.2 [11.0, 27.0]
Chapter Musculoskeletal system and connective tissue M00-M99 12 0.2 [0.1, 0.4] 2.7 4.5 [2.6, 7.9]
Chapter External causes** V01–Y98 482 8.9 [8.1, 9.7] 146.3 3.3 [3.0, 3.6]
3 Homicide*** X86-Y09 77 1.4 [1.1, 1.8] 6.3 12.2 [9.8, 15.3]
3 Suicide excluding drug-related poisonings X65-X84 & Y15-Y34 199 3.7 [3.2, 4.2] 68.2 2.9 [2.5, 3.4]
Suicide including drug-related poisonings X60-X84 & Y10-Y34 351 6.5 [5.8, 7.2] 81.9 4.3 [3.9, 4.8]
Chapter Not classiﬁed elsewhere**** – 66 1.2 [1.0, 1.6] 12.2 5.4 [4.3, 6.9]
– Other***** 18 0.3 [0.2, 0.5] 19.6 1.0 [0.6, 1.5]
* Excluding 916 categorised as drug-related poisonings (ICD10 codes: F11-16; F18-19).
** Excluding 799 categorised as drug-related poisonings (6 homicides and 152 suicides: ICD10 codes X40-X44, X60-X64, X85, Y10-Y14.
*** Including 14 cases of ‘accelerated registration’ where the coroner’s inquest is adjourned until legal proceedings are completed.
**** Including 61 cases of ‘other ill-deﬁned and unspeciﬁed causes of mortality’.
***** Other deaths: Congenitalmalformations, deformations and chromosomal abnormalities (n=8); diseases of: the blood (n=6); the genitourinary system (n<5); pregnancy,
childbirth and the pueriperium (n<5) and conditions originating in the perinatal period (n<5).
(notably, infectious/parasitic, cancer, ﬁbrosis and cirrhosis of the
liver). This is likely, in part, due to synergistic effects, including the
well-known combination of viral hepatitis and alcohol (Fu et al.,
2007; Hutchinson et al., 2005;Marrero et al., 2005;McDonald et al.,
2011). The SMR, but not CMR, for homicide also increasedmarkedly
with age, indicating an age persistent risk not present in the general
population.
Our analysis provides the ﬁrst demonstration of a highly signif-
icant, age-related increase in opioid users’ drug-related poisoning
mortality rate that persists beyond 45 years of age. This ﬁnding
Table 4b
Cause-speciﬁc CMRs and SMRs by age at risk for the opioid user cohort of 198,247 individuals and 541,891 person years.
Age-group
Cause of death and
SMR linear trend by
age-group
18–34 years, (pys =298,111) Age-group:35–44 years, (pys =175,464) 45–64 years, (pys =68,317)
n† CMR per 10k
pys [95% CI]
SMR [95% CI] n† CMR per 10k
pys [95% CI]
SMR [95% CI] n† CMR per 10k
pys [95% CI]
SMR [95% CI]
Infectious/parasitic
diseases
SMR trend p<0.001
23 0.8 [0.5, 1.2] 5.7 [3.8, 8.6] 56 3.2 [2.5, 4.1] 11.0 [8.5, 14.3] 80 11.7 [9.4, 14.6] 23.2 [18.6, 28.8]
Cancers
SMR trend p=0.003
33 1.1 [0.8, 1.6] 1.3 [0.9, 1.8] 72 4.1 [3.3, 5.2] 1.5 [1.2, 1.9] 191 28.0 [24.3, 32.2] 2.1 [1.8, 2.4]
Circulatory system
SMR trend p=0.24
71 2.4 [1.9, 3.0] 3.6 [2.9, 4.6] 143 8.1 [6.9, 9.6] 3.2 [2.7, 3.8] 204 29.9 [26.0, 34.3] 2.9 [2.5, 3.3]
Respiratory system
SMR trend p=0.24
40 1.3 [1.0, 1.8] 7.5 [5.5, 10.2] 88 5.0 [4.1, 6.2] 10.2 [8.3, 12.6] 131 19.2 [16.2, 22.8] 8.7 [7.3, 10.3]
Digestive system
SMR trend p=0.16
59 2.0 [1.5, 2.6] 5.8 [4.5, 7.5] 164 9.3 [8.0, 10.9] 6.0 [5.1, 6.9] 200 29.3 [25.5, 33.6] 7.1 [6.2, 8.2]
Diseases of liver:
SMR trend p=0.10
44 1.5 [1.1, 2.0] 6.4 [4.7, 8.5] 136 7.8 [6.6, 9.2] 6.3 [5.3, 7.4] 165 24.2 [20.7, 28.1] 7.9 [6.8, 9.2]
Alcoholic liver
disease
SMR trend p=0.75
35 1.1 [0.8, 1.6] 6.8 [4.9, 9.4] 105 6.0 [4.9, 7.2] 6.4 [5.3, 7.7] 109 16.0 [13.2, 19.3] 7.1 [5.9, 8.5]
Fibrosis and
cirrhosis of liver
SMR trend p<0.001
2 0.1 [0.0, 0.3] 2.6 [0.7, 10.5] 18 1.0 [0.6, 1.6] 6.3 [3.9, 9.9] 46 6.7 [5.0, 9.0] 14.1 [10.6, 18.9]
Homicides
SMR trend p=0.002
35 1.2 [0.8, 1.6] 8.8 [6.3, 12.2] 28 1.6 [1.1, 2.3] 15.3 [10.7, 22.3] 14 2.0 [1.2, 3.5] 27.3 [16.1, 46.0]
Suicides
SMR trend p=0.55
93 3.1 [2.5, 3.8] 2.7 [2.2, 3.3] 79 4.5 [3.6, 5.6] 3.1 [2.5, 3.9] 27 4.0 [2.7, 5.8] 3.2 [2.2, 4.6]
† Number of observed deaths.
22 M. Pierce et al. / Drug and Alcohol Dependence 146 (2015) 17–23
contrasts with routine reports of drug-related poisoning death
rates per million of population in England and Wales (Ofﬁce for
National Statistics Statistical Bulletin, 2013) which indicate a peak
rate at 30–39 years. However, ofﬁcial reporting does not take into
account differential user prevalence by age-group.
External causes, excluding drug-related poisonings, accounted
for three times the number of deaths expected (SMR 3.3; 95% CI
3.0 to 3.6). Homicide and suicide were major causes, the latter
resonating with a recent policy focus on the contribution of drug
dependency to suicide (Department of Health, 2012). The SMR for
suicide remained elevated when the subset of drug-related sui-
cides (which may include misclassiﬁed accidental overdoses) was
excluded.
The drug-related poisoning mortality risk among female opi-
oid users was lower than for men, but the gender difference was
considerably more marked among those aged under 35 years. As a
sensitivity analysis we established that, for the treatment-seeking
sub-cohort, this interaction was still evident once we adjusted for
reported behavioural risks, of injecting, problematic use of alcohol,
or benzodiazepines (test for interaction p<0.001; see supplemen-
tarymaterial). Our data do not support speculation on the potential
underlying causal effects at work here, but underscore a need for
relevant explanatory studies. A potential avenue is the observation
(Kimber et al., 2010) that females may cease drug use at an earlier
stage: use persisting into older agemay bemore severely problem-
atic, but the effect may be manifested to a greater extent among
women.
4.2. Comparison with other key studies
The excess risk reported here was considerably less than that
reported in a meta-analysis of the international literature (SMR
14.7; 95% CI 12.8 to 16.5) (Degenhardt et al., 2011). Thismay reﬂect
lower HIV prevalence and better treatment access in England com-
pared with many countries; or earlier epochs. The SMR for the
England cohort was slightly lower than that observed for an ear-
lier (1985 to 2005) Australian treatment cohort (SMR 6.5; 95% CI
6.3 to 6.7) (Degenhardt et al., 2014). It was slightly higher than
for the most readily comparable, near contemporary (2001–2006),
geographically proximal, Scottish drug treatment cohort (SMR 4.8;
95% CI 4.6 to 5.0) (Merrall et al., 2012). This may reﬂect the latter’s
inclusion of non-opioid users (35%), despite a higher proportion
injecting (48%), and younger age, demonstrating the importance
of considering the full range of salient factors when comparing
cohorts’ SMRs.
4.3. Strengths and limitations
Steps were taken to minimise false positive data linkages by
comparingminimal identiﬁerswith unique criminal justice system
(CJS) identiﬁers, removing all cases forwhich therewas evidence of
a potentially non-uniqueminimal identiﬁer. This approach applied
to the73%of identiﬁers thathadauniqueCJS identiﬁerandwascon-
servative, insofar as these CJS identiﬁersmay themselves be subject
to transcriptionerrors as a consequenceofmanual data entry.How-
ever, some misclassiﬁcation and failures-to-match may remain.
The use of self-report may underestimate levels of behavioural
risks (see Supplementarymaterial2). Therewas anabsenceof active
followupand soany cessationof declaredbehavioural riskswasnot
accounted for; the use of a short median follow up time, however,
limits any resultant bias. Additional factors contributing to excess
mortality, and common amongst this group, were not measured,
2 Supplementary material can be found by accessing the online version of this
paper at http://dx.doi.org and by entering doi:...
including: high rates of smoking, high levels of alcohol consump-
tion that is not acknowledged as problematic, low socioeconomic
status, lowquality of life, high rates of depressionandco-morbidity,
and poor diet (Copeland et al., 2012). It is also important to note
thatwhilst ourﬁndings should informmanagement of older, active,
opioid users, we are unable to make inferences about longer-term
mortality outcomes for those who desist from use at a younger
age, although this may not be the norm (Termorshuizen et al.,
2005; Hser et al., 2004). Treatment effects on mortality risk were
not considered here but are being investigated in parallel work.
Finally, although the cohort was derived from multiple national
data sources it does not, of course, represent all opioid users. Those
users not identiﬁed in either treatment or the criminal justice sys-
temsmay be less problematic and at lower risk.Whilst it is difﬁcult
to study this hidden population, future work could, potentially,
explore the extent to which cases of fatal opioid-related poisoning
haveprior criminal justiceor treatment contact, as is done routinely
in Scotland (Hecht et al., 2014).
Despite these limitations, the inclusion of users accrued from
national, treatment and non-treatment sources,with a focus on age
effects, serves to address important limitations in the existing liter-
ature identiﬁed by others (Degenhardt et al., 2011). The statistical
powerprovidedbysucha largecohort,more thandouble the largest
to date (Crump et al., 2013; Degenhardt et al., 2014; Ghodse et al.,
1998; Merrall et al., 2012), strengthens previous research interna-
tionally, particularly in respect of deaths not directly attributed to
opioid misuse.
4.4. Conclusions and implications
The opioid misusing population in the UK, and elsewhere, is
ageing (Royal College of Psychiatrists, 2011); many of those who
initiated use during the heroin ‘epidemics’ of the 1980s and 1990s,
andwho have not died or abstained, are now in their fourth or ﬁfth
decade of life. We demonstrate that health inequalities between
opioid users and the general population persist and, for some dis-
eases, widenwith age. These ﬁndings underline the importance for
public health policy and treatment providers of delivering effective
addiction treatment for older age groups, who are characterised
by multiple and complex health problems. Importantly, as the
opioid using population ages, so their risk of death due to drug-
related poisoning is likely to increase: national targets need to
adjust for age in order effectively to monitor the impact of policies
with the aim of reducing drug-related poisoning deaths. Crucially,
the new health information on drug-related poisoning mortality
risk in older age as presented here should be promoted to opioid
users themselves, to emphasise that their risk of overdose does not
decline, but rather increases, with age. The increased SMRs with
age for homicide and cancer (in addition to infectious diseases and
liver ﬁbrosis/cirrhosis) also merit attention.
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